BIORETEC OY (0TN) - Total Liabilities
Based on the latest financial reports, BIORETEC OY (0TN) has total liabilities worth €1.92 Million EUR (≈ $2.24 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of BIORETEC OY to track the company's year-over-year net asset growth rate.
BIORETEC OY - Total Liabilities Trend (2021–2025)
This chart illustrates how BIORETEC OY's total liabilities have evolved over time, based on quarterly financial data.
BIORETEC OY Competitors by Total Liabilities
The table below lists competitors of BIORETEC OY ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crookes Brothers Ltd
JSE:CKS
|
South Africa | ZAC892.52 Million |
|
Safestore Holdings Plc
LSE:SAFE
|
UK | GBX1.30 Billion |
|
FINEDIGITAL Inc
KQ:038950
|
Korea | ₩11.17 Billion |
|
FAWER Automotive Parts Ltd Co
SHE:200030
|
China | HK$9.40 Billion |
|
IRIDEX Corporation
NASDAQ:IRIX
|
USA | $24.23 Million |
|
Cosmos Technology International Berhad
KLSE:0261
|
Malaysia | RM13.10 Million |
|
Ortivus AB ser. B
ST:ORTI-B
|
Sweden | Skr48.52 Million |
|
Dongsung Pharm
KO:002210
|
Korea | ₩107.40 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down BIORETEC OY's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIORETEC OY market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIORETEC OY's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIORETEC OY (2021–2025)
The table below shows the annual total liabilities of BIORETEC OY from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.92 Million ≈ $2.24 Million |
+10.39% |
| 2024-12-31 | €1.74 Million ≈ $2.03 Million |
-28.46% |
| 2023-12-31 | €2.43 Million ≈ $2.84 Million |
+54.95% |
| 2022-12-31 | €1.57 Million ≈ $1.83 Million |
-63.08% |
| 2021-12-31 | €4.24 Million ≈ $4.96 Million |
-- |
About BIORETEC OY
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; A… Read more